China SXT Pharmaceuticals, Inc. (SXTC)
USD 2.5
(0.4%)
USD 2.5
(0.4%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -9.42 Million USD | 30.77% |
| 2023 | -13.61 Million USD | -0.99% |
| 2022 | -13.47 Million USD | -1.42% |
| 2021 | -13.28 Million USD | -2259.85% |
| 2020 | -563.15 Thousand USD | 93.65% |
| 2019 | -8.86 Million USD | -4964.61% |
| 2018 | -175.13 Thousand USD | -174.02% |
| 2017 | 236.59 Thousand USD | -49.42% |
| 2016 | 467.78 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q4 | -9.42 Million USD | -9.43% |
| 2024 Q2 | -8.31 Million USD | -4.59% |
| 2024 FY | -9.42 Million USD | 30.72% |
| 2024 Q3 | -8.61 Million USD | -3.57% |
| 2024 Q1 | -7.94 Million USD | 41.6% |
| 2023 FY | -13.61 Million USD | -0.99% |
| 2023 Q2 | -1.77 Million USD | 0.0% |
| 2023 Q3 | -8.46 Million USD | -376.98% |
| 2023 Q1 | -1.77 Million USD | 86.83% |
| 2023 Q4 | -13.61 Million USD | -60.78% |
| 2022 Q3 | -4.78 Million USD | -65599.53% |
| 2022 FY | -13.47 Million USD | -1.42% |
| 2022 Q2 | -7279.00 USD | -100.34% |
| 2022 Q4 | -13.47 Million USD | -181.83% |
| 2022 Q1 | 2.11 Million USD | 115.88% |
| 2021 Q2 | -10.29 Million USD | 0.0% |
| 2021 FY | -13.28 Million USD | -2259.85% |
| 2021 Q3 | -1.14 Million USD | 88.91% |
| 2021 Q1 | -10.29 Million USD | -1727.65% |
| 2021 Q4 | -13.28 Million USD | -1064.58% |
| 2020 FY | -563.15 Thousand USD | 93.65% |
| 2020 Q2 | -2.33 Million USD | -369.42% |
| 2020 Q4 | -563.15 Thousand USD | 0.0% |
| 2020 Q3 | -563.15 Thousand USD | 75.85% |
| 2020 Q1 | -496.68 Thousand USD | 94.4% |
| 2019 Q1 | 163.33 Thousand USD | 193.26% |
| 2019 Q4 | -8.86 Million USD | -39.78% |
| 2019 Q3 | -6.34 Million USD | -25908.86% |
| 2019 Q2 | -24.39 Thousand USD | -114.94% |
| 2019 FY | -8.86 Million USD | -4964.61% |
| 2018 Q1 | 65.57 Thousand USD | -72.29% |
| 2018 Q3 | 279.98 Thousand USD | 0.0% |
| 2018 Q4 | -175.13 Thousand USD | -162.55% |
| 2018 FY | -175.13 Thousand USD | -174.02% |
| 2017 Q4 | 236.59 Thousand USD | 0.0% |
| 2017 FY | 236.59 Thousand USD | -49.42% |
| 2016 FY | 467.78 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 102.166% |
| Embecta Corp. | 1.31 Billion USD | 100.719% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 110.01% |
| Dynavax Technologies Corporation | 106.63 Million USD | 108.843% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 102.056% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 102.179% |
| PainReform Ltd. | -7.95 Million USD | -18.613% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 112.581% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 39.687% |
| SCYNEXIS, Inc. | -19.35 Million USD | 51.268% |
| Cosmos Health Inc. | 8.59 Million USD | 209.766% |
| Journey Medical Corporation | -9.7 Million USD | 2.876% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 39.687% |
| Safety Shot Inc | -2.28 Million USD | -312.793% |
| Alpha Teknova, Inc. | 1.97 Million USD | 577.697% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 92.792% |
| Bright Green Corporation | 1.84 Million USD | 612.006% |
| Procaps Group, S.A. | 242.93 Million USD | 103.882% |
| Theratechnologies Inc. | 24.87 Million USD | 137.915% |
| Harrow Health, Inc. | 116.41 Million USD | 108.1% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -274.196% |
| Biofrontera Inc. | 4.05 Million USD | 332.488% |
| DURECT Corporation | -7.65 Million USD | -23.2% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 71.874% |
| Cronos Group Inc. | -663.32 Million USD | 98.578% |
| OptiNose, Inc. | 58.06 Million USD | 116.24% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 101.513% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 35.289% |
| RedHill Biopharma Ltd. | -5.18 Million USD | -81.829% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 162.81% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | -48.274% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 8924.462% |
| Radius Health, Inc. | 359.28 Million USD | 102.625% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 4881.593% |
| ProPhase Labs, Inc. | 19.23 Million USD | 149.034% |
| Phibro Animal Health Corporation | 454.84 Million USD | 102.073% |
| Procaps Group S.A. | 242.93 Million USD | 103.882% |
| Alvotech | 1.06 Billion USD | 100.886% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 356.382% |
| Viatris Inc. | 17.13 Billion USD | 100.055% |
| Rockwell Medical, Inc. | 4.45 Million USD | 311.619% |
| Aytu BioPharma, Inc. | -4.87 Million USD | -93.351% |
| SIGA Technologies, Inc. | -148.68 Million USD | 93.658% |
| Tilray Brands, Inc. | 158.97 Million USD | 105.932% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 107.736% |
| Shineco, Inc. | 29.29 Million USD | 132.194% |
| PetIQ, Inc. | 351.93 Million USD | 102.679% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | -225.003% |
| Incannex Healthcare Limited | -5.48 Million USD | -71.919% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 105.319% |
| Alimera Sciences, Inc. | 55.3 Million USD | 117.049% |
| Silver Spike Investment Corp. | -32.61 Million USD | 71.085% |
| Assertio Holdings, Inc. | -32.52 Million USD | 71.011% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -533.411% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | -86.344% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | -95.881% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -14.808% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 323.612% |
| Hempacco Co., Inc. | 13.61 Million USD | 169.262% |
| Talphera, Inc. | -5.72 Million USD | -64.827% |
| Alvotech | 1.06 Billion USD | 100.886% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 231.977% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 90.249% |
| Currenc Group, Inc. | -16.57 Million USD | 43.102% |
| Kamada Ltd. | -46.43 Million USD | 79.691% |
| Indivior PLC | -33.95 Million USD | 72.226% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 3718.831% |
| Flora Growth Corp. | -713 Thousand USD | -1222.543% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | -14.808% |
| Evolus, Inc. | 63.7 Million USD | 114.801% |
| HUTCHMED (China) Limited | -197.45 Million USD | 95.224% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 101.968% |
| Akanda Corp. | 3.9 Million USD | 341.484% |